This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Cerner's (CERN) Latest Offering to Improve RCM Portfolio
by Zacks Equity Research
Cerner's (CERN) latest offering is likely to streamline and automate revenue cycle via interoperability and enhanced usability.
Health Catalyst (HCAT) Reports Break-Even Earnings for Q2
by Zacks Equity Research
Health Catalyst (HCAT) delivered earnings and revenue surprises of 100.00% and 5.20%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Health Catalyst (HCAT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Health Catalyst (HCAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for July 21st
by Zacks Equity Research
CNO, CLOV, DMAC, HCAT and IMAX have been added to the Zacks Rank #5 (Strong Sell) List on July 21, 2021.
Health Catalyst (HCAT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Health Catalyst (HCAT) delivered earnings and revenue surprises of 53.85% and 3.25%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Health Catalyst (HCAT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Health Catalyst (HCAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Health Catalyst (HCAT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Health Catalyst (HCAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Health Catalyst (HCAT) Catches Eye: Stock Jumps 5.1%
by Zacks Equity Research
Health Catalyst (HCAT) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Health Catalyst (HCAT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Health Catalyst (HCAT) delivered earnings and revenue surprises of 22.22% and 5.69%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Health Catalyst (HCAT) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Health Catalyst (HCAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Schrodinger (SDGR) Catches Eye: Stock Jumps 9.3%
by Zacks Equity Research
Schrodinger (SDGR) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
1Life Healthcare (ONEM) Soars: Stock Adds 9% in Session
by Zacks Equity Research
1Life Healthcare (ONEM) saw a big move last session, as its shares jumped 9% on the day, amid huge volumes.
Health Catalyst (HCAT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Health Catalyst (HCAT) delivered earnings and revenue surprises of 37.50% and 3.24%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Health Catalyst (HCAT)?
by Zacks Equity Research
Health Catalyst (HCAT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
iRhythm (IRTC) Looks Good: Stock Adds 9.6% in Session
by Zacks Equity Research
iRhythm (IRTC) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
Health Catalyst (HCAT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Health Catalyst (HCAT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Medical Product Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
Health Catalyst's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Health Catalyst.
Medical Info Systems Outlook Bright Amid Coronavirus Crisis
by Urmimala Biswas
Despite the coronavirus-led worldwide sales disruption, Medical Info Systems is one of the few sectors witnessing industry-wide growth.
The Zacks Analyst Blog Highlights: LOGI, GO, GFL, HCAT and VIE
by Zacks Equity Research
The Zacks Analyst Blog Highlights: LOGI, GO, GFL, HCAT and VIE
Silver Standard (SSRM) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Silver Standard's (SSRM) first-quarter results are likely to reflect higher units of gold sold and increasing gold prices.
Should You Buy Health Catalyst (HCAT) Ahead of Earnings?
by Zacks Equity Research
Health Catalyst (HCAT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
6 Top Stocks to Buy Ahead of Earnings Results This Week
by Nalak Das
Despite the negative earnings trend, a handful of stocks with a favorable Zacks Rank are poised to beat earnings estimates this week.
What's in Store for GW Pharmaceuticals (GWPH) in Q1 Earnings?
by Zacks Equity Research
GW Pharmaceuticals (GWPH) might have registered slower international sales growth from procedural deferrals due to coronavirus pandemic in Q1.
What's in the Cards for CVS Health (CVS) in Q1 Earnings?
by Zacks Equity Research
We expect CVS Health (CVS) to have gained from Aetna's addition of new Individual and Group Medicare Advantage members in Q1.